The Dry Eye Chronicles by Kala Pharmaceuticals

EPISODE 5 : Stepping Boldly Forward with Short-Term Rx Treatment for Dry Eye (PART 2)

Preeya Gupta, MD & Christopher Starr, MD, FACS

With a burgeoning influx of Dry Eye patients coming in daily to practices, there is a need to embrace the prevalence and natural history of Dry Eye Flares—or an acute worsening of symptoms. This is a critical first step when identifying the type of Dry Eye patient, whether for acute or chronic care management. In this podcast, Christopher Starr, MD, joins Preeya Gupta, MD, to discuss the potential benefits of EYSUVIS® as a short-term Rx treatment for Dry Eye, the IOP safety profile, and the importance of patient empowerment when initiating therapy for Dry Eye Flares.

EPISODE 5 : Stepping Boldly Forward with Short-Term Rx Treatment for Dry Eye (PART 1)

Preeya Gupta, MD & Christopher Starr, MD, FACS

With a burgeoning influx of Dry Eye patients coming in daily to practices, there is a need to embrace the prevalence and natural history of Dry Eye Flares—or an acute worsening of symptoms. This is a critical first step when identifying the type of Dry Eye patient, whether for acute or chronic care management. In this podcast, Christopher Starr, MD, joins Preeya Gupta, MD, to discuss the potential benefits of EYSUVIS® as a short-term Rx treatment for Dry Eye, the IOP safety profile, and the importance of patient empowerment when initiating therapy for Dry Eye Flares.

Episode 5 - Stepping Boldly Forward with Short-Term Rx Treatment for Dry Eye Part 2 (OD)

Walt Whitley, OD, MBA, FAAO, & Marc Bloomenstein, OD, FAAO

With a burgeoning influx of Dry Eye patients coming in daily to practices, there is a need to embrace the prevalence and natural history of Dry Eye Flares—or an acute worsening of symptoms. This is a critical first step when identifying the type of Dry Eye patient, whether for acute or chronic care management. In this podcast, Dr. Marc Bloomenstein, OD, FAAO joins Walt Whitley, OD, MBA, FAAO, to discuss the potential benefits of EYSUVIS® as a short-term Rx treatment for Dry Eye, the IOP safety profile, and the importance of patient empowerment when initiating therapy for Dry Eye Flares.

Episode 5 - Stepping Boldly Forward with Short-Term Rx Treatment for Dry Eye Part 1 (OD)

Walt Whitley, OD, MBA, FAAO, & Marc Bloomenstein, OD, FAAO

With a burgeoning influx of Dry Eye patients coming in daily to practices, there is a need to embrace the prevalence and natural history of Dry Eye Flares—or an acute worsening of symptoms. This is a critical first step when identifying the type of Dry Eye patient, whether for acute or chronic care management. In this podcast, Dr. Marc Bloomenstein, OD, FAAO joins Walt Whitley, OD, MBA, FAAO, to discuss the potential benefits of EYSUVIS® as a short-term Rx treatment for Dry Eye, the IOP safety profile, and the importance of patient empowerment when initiating therapy for Dry Eye Flares.

EPISODE 4: Thinking Differently: An In-Depth Look at Dry Eye Flares

Preeya Gupta, MD, & Sarah Darbandi, MD

Most of us, including many clinicians, can get lost in the forest for the trees when trying to understand Dry Eye and Dry Eye Flares. With up to 70-80% of Dry Eye patients in some practices suffering from Dry Eye Flares, it’s important for practitioners to understand where these numbers are coming from, and what they can do to lower them. In this podcast, Dr. Sarah Darbandi, MD, joins Preeya Gupta, MD, to discuss the importance of communication surrounding triggers and treatment options with patients, as well as keeping practitioners up-to-date with the current literature to better understand the pathophysiology of the condition.

EPISODE 4: Thinking Differently: An In-Depth Look at Dry Eye Flares

Walt Whitley, OD, MBA, FAAO, & Arthur B. Epstein, OD, FAAO

Most of us, including many clinicians, can get lost in the forest for the trees when trying to understand Dry Eye and Dry Eye Flares. With up to 70-80% of Dry Eye patients in some practices suffering from Dry Eye Flares, it’s important for practitioners to understand where these numbers are coming from, and what they can do to lower them. In this podcast, Dr. Art Epstein, OD, FAAO, joins Walt Whitley, OD, MBA, FAAO, to discuss the importance of communication surrounding triggers and treatment options with patients, as well as keeping practitioners up-to-date with the current literature to better understand the pathophysiology of the condition.

EPISODE 3: To Be A Dry Eye Detective: Patient Identification Through Clinical Experience

Walt Whitley, OD, MBA, FAAO, & Scott Hauswirth, OD, FAAO

The dry eye population can present with different challenges along with varied intensity and frequency of Dry Eye Flares, among other differences that can affect how optometrists formulate their treatment strategy. In this episode, Scott Hauswirth, OD, FAAO, joins Walt Whitley, OD, MBA, FAAO to discuss how EYSUVIS™ (loteprednol etabonate ophthalmic suspension) 0.25%* can be part of an appropriate treatment plan for many of their dry eye patients—from the noncompliant patient to the patient using artificial tears still suffering from Dry Eye Flares to co-managing the pre-op patient preparing for cataract or refractive surgery—by asking proactive questions.

EPISODE 3: To Be A Dry Eye Detective: Patient Identification Through Clinical Experience

Preeya Gupta, MD, & Mitchell A. Jackson, MD

The dry eye population can present with different challenges along with varied intensity and frequency of Dry Eye Flares, among other differences that can affect how ophthalmologists formulate their treatment strategy. In this episode, Mitchell A. Jackson, MD, joins Preeya Gupta, MD to discuss how EYSUVIS™ (loteprednol etabonate ophthalmic suspension) 0.25%* can be part of an appropriate treatment plan for many of their dry eye patients—from the non-compliant patient to the patient using artificial tears still suffering from Dry Eye Flares to the pre-op patient preparing for cataract or refractive surgery.

Walt Whitley, OD, MBA, FAAO, & Selina McGee, OD, FAAO

The journey of the dry eye patient can be challenging. They often go to multiple practitioners and try several at-home remedies in an attempt to have their condition taken seriously and get some relief. In this podcast, Selina McGee, OD, FAAO, joins Walt Whitley, OD, MBA, FAAO to discuss the importance of building trust to empower dry eye patients in order to confidently take back control of their condition, as well as how EYSUVIS™ (loteprednol etabonate ophthalmic suspension) 0.25%*—the first FDA-approved steroid for the short-term treatment (up to two weeks) of the signs and symptoms of DED—and its AMPPLIFY® technology may benefit their patients.

Preeya Gupta, MD, & Cynthia Matossian, MD, FACS, ABES

The journey of the dry eye patient can be challenging. They often go to multiple practitioners and try several at-home remedies in an attempt to have their condition taken seriously and get some relief. In this podcast, Cynthia Matossian, MD, FACS, ABES joins Preeya Gupta, MD to discuss the importance of building trust to empower dry eye patients to take back control in order to better manage their condition, as well as how EYSUVIS™ (loteprednol etabonate ophthalmic suspension) 0.25%*—the first FDA-approved steroid for the short-term treatment (up to two weeks) of the signs and symptoms of DED—and its AMPPLIFY® technology may benefit their patients.